These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
688 related articles for article (PubMed ID: 28726212)
41. An Update on New and Existing Treatments for the Management of Melasma. Gan C; Rodrigues M Am J Clin Dermatol; 2024 Jun; ():. PubMed ID: 38896402 [TBL] [Abstract][Full Text] [Related]
42. Oral Tranexamic Acid with Fluocinolone-Based Triple Combination Cream Versus Fluocinolone-Based Triple Combination Cream Alone in Melasma: An Open Labeled Randomized Comparative Trial. Padhi T; Pradhan S Indian J Dermatol; 2015; 60(5):520. PubMed ID: 26538719 [TBL] [Abstract][Full Text] [Related]
43. The evolution of melasma therapy: targeting melanosomes using low-fluence Q-switched neodymium-doped yttrium aluminium garnet lasers. Kauvar AN Semin Cutan Med Surg; 2012 Jun; 31(2):126-32. PubMed ID: 22640433 [TBL] [Abstract][Full Text] [Related]
44. Future therapies in melasma: What lies ahead? Sarkar R; Bansal A; Ailawadi P Indian J Dermatol Venereol Leprol; 2020; 86(1):8-17. PubMed ID: 31793496 [TBL] [Abstract][Full Text] [Related]
45. Management of Melasma: Laser and Other Therapies-Review Study. Jiryis B; Toledano O; Avitan-Hersh E; Khamaysi Z J Clin Med; 2024 Mar; 13(5):. PubMed ID: 38592701 [TBL] [Abstract][Full Text] [Related]
47. Tranexamic Acid in the Treatment of Melasma: A Review of the Literature. Perper M; Eber AE; Fayne R; Verne SH; Magno RJ; Cervantes J; ALharbi M; ALOmair I; Alfuraih A; Nouri K Am J Clin Dermatol; 2017 Jun; 18(3):373-381. PubMed ID: 28283893 [TBL] [Abstract][Full Text] [Related]
49. What should be considered in treatment of melasma. Kang HY; Ortonne JP Ann Dermatol; 2010 Nov; 22(4):373-8. PubMed ID: 21165205 [TBL] [Abstract][Full Text] [Related]
50. Optimizing Q-switched lasers for melasma and acquired dermal melanoses. Aurangabadkar SJ Indian J Dermatol Venereol Leprol; 2019; 85(1):10-17. PubMed ID: 30027914 [TBL] [Abstract][Full Text] [Related]
52. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Sarkar R; Kaur C; Bhalla M; Kanwar AJ Dermatol Surg; 2002 Sep; 28(9):828-32; discussion 832. PubMed ID: 12269877 [TBL] [Abstract][Full Text] [Related]
53. Treatment of melasma. Rendon M; Berneburg M; Arellano I; Picardo M J Am Acad Dermatol; 2006 May; 54(5 Suppl 2):S272-81. PubMed ID: 16631968 [TBL] [Abstract][Full Text] [Related]
54. Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up. Lajevardi V; Ghayoumi A; Abedini R; Hosseini H; Goodarzi A; Akbari Z; Hedayat K J Cosmet Dermatol; 2017 Jun; 16(2):235-242. PubMed ID: 27762489 [TBL] [Abstract][Full Text] [Related]
55. Lasers, lights, and compounds for melasma in aesthetics. Kamal K; Heitmiller K; Christman M Clin Dermatol; 2022; 40(3):249-255. PubMed ID: 34838653 [TBL] [Abstract][Full Text] [Related]
56. The treatment of melasma: a review of clinical trials. Gupta AK; Gover MD; Nouri K; Taylor S J Am Acad Dermatol; 2006 Dec; 55(6):1048-65. PubMed ID: 17097400 [TBL] [Abstract][Full Text] [Related]
57. Chemical peels for melasma in dark-skinned patients. Sarkar R; Bansal S; Garg VK J Cutan Aesthet Surg; 2012 Oct; 5(4):247-53. PubMed ID: 23378706 [TBL] [Abstract][Full Text] [Related]
59. Hyperpigmentation Disorders in Hispanic Population in the United States. Rendon MI J Drugs Dermatol; 2019 Mar; 18(3):s112-114. PubMed ID: 30909363 [TBL] [Abstract][Full Text] [Related]
60. Hyperpigmentation Disorders in Hispanic Population in the United States. Rendon MI J Drugs Dermatol; 2019 Mar; 18(3):s112-114. PubMed ID: 30909362 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]